QOL Medical, LLC receives FDA approval of Sucraid® (Sacrosidase) Oral Solution single-use containers for Patients with Congenital Sucrase-Isomaltase Deficiency (CSID)

FDA approved

QOL Medical, LLC, a ground-breaking, rare disease pharmaceutical company, announced today that the United States (U.S.) Food & Drug Administration (FDA) approved Sucraid® single-use containers for patients more than 33 lb (15 kg) with Congenital Sucrase-Isomaltase Deficiency (CSID).

Currently, Sucraid® (sacrosidase) Oral Solution is the only pharmaceutical treatment for CSID in children and adults. Sucraid® is an enzyme replacement therapy for genetically determined sucrase deficiency, which is part of CSID. Sucraid® helps the breakdown and absorption of sucrose (table sugar) from the intestine, which relieve the gastrointestinal symptoms of CSID. Now Sucraid® is available in both Sucraid® multi-dose bottles and Sucraid® single-use containers.

About Sucraid

Mechanism of Action of Sacrosidase

  • API-Sacrosidase
  • Description-Sacrosidase (trade name Sucraid) is a medication used to replace sucrase in people lacking this enzyme. It is available as an oral solution. Sucraid is approved by the U.S. Food and Drug Administration (FDA) for the therapy of the genetically determined sucrase deficiency that is part of the Congenital Sucrase-Isomaltase Deficiency (CSID). Sacrosidase assists in the breakdown of sugar/sucrose into simpler forms and is useful for the relief of gastrointestinal symptoms that are associated with CSID.
  • Indication-For the treatment of congenital sucrose-isomaltase deficiency (CSID).
  • Class –Glycoside hydrolases
  • Mechanism of Action –Sacrosidase is a [beta]-fructofuranoside fructohydrolase that hydrolyzes sucrose. Unlike human intestinal sucrase-isomaltase, it has no activity with oligosaccharides containing 1,6 glucosyl bonds.
  • Biologic Classification -Protein Based Therapies
IMPORTANT SAFETY INFORMATION FOR SUCRAID®  (SACROSIDASE) ORAL SOLUTION
  • Sucraid® may cause a serious allergic reaction. If you notice any swelling or have difficulty breathing, get emergency help right away.

  • Sucraid® does not break down some sugars that come from the digestion of starch.  You may need to restrict the amount of starch in your diet. Your doctor will tell you if you should restrict starch in your diet.

  • Tell your doctor if you are allergic to, have ever had a reaction to, or have ever had difficulty taking yeast, yeast products, papain, or glycerin (glycerol).

  • Tell your doctor if you have diabetes, as your blood glucose levels may change if you begin taking Sucraid®. Your doctor will tell you if your diet or diabetes medicines need to be changed.

  • Some patients treated with Sucraid® may have worse abdominal pain, vomiting, nausea, or diarrhea.  Constipation, difficulty sleeping, headache, nervousness, and dehydration have also occurred. Check with your doctor if you notice these or other side effects.

  • Sucraid® has not been tested to see if it works in patients with secondary (acquired) sucrase deficiency.

  • NEVER HEAT SUCRAID® OR PUT IT IN WARM OR HOT BEVERAGES OR INFANT FORMULA. Do not mix Sucraid® with fruit juice or take it with fruit juice. Take Sucraid® as prescribed by your doctor. Normally half of the dose of Sucraid® is taken before a meal or snack and the other half is taken during the meal or snack. 

  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light.

“If untreated, patients living with this chronic condition suffer from debilitating symptoms. We are always looking for ways to improve their quality of life. These new single-use containers will make it easier for them to manage their medication,” said Weng Tao, MD, PhD, COO of QOL Medical, LLC. “FDA’s approval of Sucraid® single-use containers, with three-day room temperature stability, offer greater convenience for CSID patients on the go.”

People with CSID are unable to properly digest sucrose (table sugar), which is found naturally in many fruits and vegetables, as well as added to many processed foods. In adolescents and adults, CSID has been characterized by symptoms of chronic abdominal pain, gas, loose stools, and diarrhea, which overlap with common irritable bowel syndrome (IBS) symptoms. In infants, CSID classically presents as explosive watery diarrhea, failure to thrive, diaper rash, irritability, and acidic stools.

About QOL Medical, LLC

QOL Medical is a specialty biopharmaceutical company dedicated to improving clinical outcomes and overall quality of life for patients with rare diseases. QOL Medical is a patient-centric company founded in 2003 to focus on the acquisition and commercialization of orphan and gastrointestinal products in underserved markets.

Weblink: https://www.chemrobotics.com

 

 

 

Related posts

FRAC 2024 POSTER PUBLISHED: INTRODUCTION OF TAVABOROLE ACTIVE INGREDIENT IN GROUP 54

August 2023 Approval Update: Sage and Biogen’s Zurzuvae™ (Zuranolone) notched FDA approval for the Treatment of Women with Postpartum Depression

March 2023 Approval Update – Pharming’s Leniolisib Gains FDA Approval for Treatment for Activated Phosphoinositide 3-Kinase Delta Syndrome